Pulmotect
Phase 2Pulmotect’s lead product, PUL-042, is a clinical stage inhaled therapeutic that stimulates the innate immune system in the lungs to provide immediate and effective protection against viral, bacterial and fungal pathogens.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $7.8M
About
Pulmotect’s lead product, PUL-042, is a clinical stage inhaled therapeutic that stimulates the innate immune system in the lungs to provide immediate and effective protection against viral, bacterial and fungal pathogens.
Drug DeliverySmall Molecules
Funding History
2Total raised:$7.8M
Grant$2.3MAug 15, 2019
Series A$5.5MMay 15, 2017